Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes - PubMed (original) (raw)
. 2011 Oct;179(4):1608-15.
doi: 10.1016/j.ajpath.2011.06.018. Epub 2011 Sep 1.
Andrea P Subhawong, Seung-Mo Hong, Michael G Goggins, Elizabeth A Montgomery, Edward Gabrielson, George J Netto, Jonathan I Epstein, Tamara L Lotan, William H Westra, Ie-Ming Shih, Christine A Iacobuzio-Donahue, Anirban Maitra, Qing K Li, Charles G Eberhart, Janis M Taube, Dinesh Rakheja, Robert J Kurman, T C Wu, Richard B Roden, Pedram Argani, Angelo M De Marzo, Luigi Terracciano, Michael Torbenson, Alan K Meeker
Affiliations
- PMID: 21888887
- PMCID: PMC3181356
- DOI: 10.1016/j.ajpath.2011.06.018
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes
Christopher M Heaphy et al. Am J Pathol. 2011 Oct.
Abstract
Approximately 10% to 15% of human cancers lack detectable telomerase activity, and a subset of these maintain telomere lengths by the telomerase-independent telomere maintenance mechanism termed alternative lengthening of telomeres (ALT). The ALT phenotype, relatively common in subtypes of sarcomas and astrocytomas, has rarely been reported in epithelial malignancies. However, the prevalence of ALT has not been thoroughly assessed across all cancer types. We therefore comprehensively surveyed the ALT phenotype in a broad range of human cancers. In total, two independent sets comprising 6110 primary tumors from 94 different cancer subtypes, 541 benign neoplasms, and 264 normal tissue samples were assessed by combined telomere-specific fluorescence in situ hybridization and immunofluorescence labeling for PML protein. Overall, ALT was observed in 3.73% (228/6110) of all tumor specimens, but was not observed in benign neoplasms or normal tissues. This is the first report of ALT in carcinomas arising from the bladder, cervix, endometrium, esophagus, gallbladder, kidney, liver, and lung. Additionally, this is the first report of ALT in medulloblastomas, oligodendrogliomas, meningiomas, schwannomas, and pediatric glioblastoma multiformes. Previous studies have shown associations between ALT status and prognosis in some tumor types; thus, further studies are warranted to assess the potential prognostic significance and unique biology of ALT-positive tumors. These findings may have therapeutic consequences, because ALT-positive cancers are predicted to be resistant to anti-telomerase therapies.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Figures
Figure 1
Representative examples of ALT-negative and ALT-positive tumors. A and B: Representative invasive urothelial carcinomas. In the ALT-negative case (A), robust telomere signals are present in tumor cells and adjacent stromal cells (asterisks). In the ALT-positive case (B), distinctive large, very bright intranuclear foci of telomere FISH signals mark ALT-associated telomeric foci throughout the tumor cells (arrows). Note the marked heterogeneity in the telomere signals, where visible, in the cancer cells. C–F: Representative ALT-positive cases of renal sarcomatoid carcinoma (C), anaplastic medulloblastoma (D), oligodendroglioma (E), and angiosarcoma (F). In all images (A–F), the DNA is stained with DAPI (blue) and telomere DNA is stained with the Cy3-labeled telomere-specific PNA probe (red). Two cases (E and F) are shown with costaining of PML protein (green), to demonstrate colocalization to most of the ALT-associated telomeric foci (arrows). The inset for each case highlights a typical APB that contains a targetoid appearance of telomere signal with a peripheral rim of PML protein. Original magnification: ×400 (A–F); ×1000 (inset).
Similar articles
- The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression.
Subhawong AP, Heaphy CM, Argani P, Konishi Y, Kouprina N, Nassar H, Vang R, Meeker AK. Subhawong AP, et al. Mod Pathol. 2009 Nov;22(11):1423-31. doi: 10.1038/modpathol.2009.125. Epub 2009 Sep 4. Mod Pathol. 2009. PMID: 19734843 - Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S, Baldi C, Pietsch T, Donofrio V, Pollo B, Antonelli M, Massimino M, Giangaspero F, Buttarelli FR. Minasi S, et al. J Neurooncol. 2019 May;142(3):435-444. doi: 10.1007/s11060-019-03127-w. Epub 2019 Mar 4. J Neurooncol. 2019. PMID: 30830680 - A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas.
Henson JD, Hannay JA, McCarthy SW, Royds JA, Yeager TR, Robinson RA, Wharton SB, Jellinek DA, Arbuckle SM, Yoo J, Robinson BG, Learoyd DL, Stalley PD, Bonar SF, Yu D, Pollock RE, Reddel RR. Henson JD, et al. Clin Cancer Res. 2005 Jan 1;11(1):217-25. Clin Cancer Res. 2005. PMID: 15671549 - Telomere Length Maintenance in Cancer: At the Crossroad between Telomerase and Alternative Lengthening of Telomeres (ALT).
De Vitis M, Berardinelli F, Sgura A. De Vitis M, et al. Int J Mol Sci. 2018 Feb 18;19(2):606. doi: 10.3390/ijms19020606. Int J Mol Sci. 2018. PMID: 29463031 Free PMC article. Review. - Telomere maintenance mechanisms in cancer: telomerase, ALT or lack thereof.
Claude E, Decottignies A. Claude E, et al. Curr Opin Genet Dev. 2020 Feb;60:1-8. doi: 10.1016/j.gde.2020.01.002. Epub 2020 Feb 27. Curr Opin Genet Dev. 2020. PMID: 32114293 Review.
Cited by
- LAP2α orchestrates alternative lengthening of telomeres suppression through telomeric heterochromatin regulation with HDAC1: unveiling a potential therapeutic target.
Wang B, Kou H, Wang Y, Zhang Q, Jiang D, Wang J, Zhao Z, Zhou Y, Zhang M, Sui L, Zhao M, Liu Y, Liu Y, Shi L, Wang F. Wang B, et al. Cell Death Dis. 2024 Oct 19;15(10):761. doi: 10.1038/s41419-024-07116-4. Cell Death Dis. 2024. PMID: 39426946 - Telomere Length and Telomerase Activity as Potential Biomarkers for Gastrointestinal Cancer.
Loukopoulou C, Nikolouzakis T, Koliarakis I, Vakonaki E, Tsiaoussis J. Loukopoulou C, et al. Cancers (Basel). 2024 Oct 1;16(19):3370. doi: 10.3390/cancers16193370. Cancers (Basel). 2024. PMID: 39409990 Free PMC article. Review. - Prevalence of alternative lengthening of telomeres in pediatric sarcomas determined by the telomeric DNA C-circle assay.
Burrow TA, Koneru B, Macha SJ, Sun W, Barr FG, Triche TJ, Reynolds CP. Burrow TA, et al. Front Oncol. 2024 Aug 19;14:1399442. doi: 10.3389/fonc.2024.1399442. eCollection 2024. Front Oncol. 2024. PMID: 39224814 Free PMC article. - Interleukin 4 and cancer resistance in glioblastoma multiforme.
Detchou D, Barrie U. Detchou D, et al. Neurosurg Rev. 2024 Aug 21;47(1):448. doi: 10.1007/s10143-024-02695-4. Neurosurg Rev. 2024. PMID: 39164434 Review. - Neotelomeres and telomere-spanning chromosomal arm fusions in cancer genomes revealed by long-read sequencing.
Tan KT, Slevin MK, Leibowitz ML, Garrity-Janger M, Shan J, Li H, Meyerson M. Tan KT, et al. Cell Genom. 2024 Jul 10;4(7):100588. doi: 10.1016/j.xgen.2024.100588. Epub 2024 Jun 24. Cell Genom. 2024. PMID: 38917803 Free PMC article.
References
- Blackburn E.H. Structure and function of telomeres. Nature. 1991;350:569–573. - PubMed
- Palm W., de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008;42:301–334. - PubMed
- de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100–2110. - PubMed
Publication types
MeSH terms
Grants and funding
- P50 CA058236/CA/NCI NIH HHS/United States
- P50 CA88843/CA/NCI NIH HHS/United States
- P50 CA098252/CA/NCI NIH HHS/United States
- P50 CA58236/CA/NCI NIH HHS/United States
- R01 CA113669/CA/NCI NIH HHS/United States
- T32 CA067751/CA/NCI NIH HHS/United States
- P50 CA088843/CA/NCI NIH HHS/United States
- R01 NS055089/NS/NINDS NIH HHS/United States
- P50 CA062924/CA/NCI NIH HHS/United States
- P50 CA62924/CA/NCI NIH HHS/United States
- P50 CA058184/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources